Matches in Wikidata for { <http://www.wikidata.org/entity/Q66071395> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q66071395 description "clinical trial" @default.
- Q66071395 description "ensayu clínicu" @default.
- Q66071395 description "klinisch onderzoek" @default.
- Q66071395 description "клінічне випробування" @default.
- Q66071395 name "Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants" @default.
- Q66071395 name "Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants" @default.
- Q66071395 type Item @default.
- Q66071395 label "Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants" @default.
- Q66071395 label "Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants" @default.
- Q66071395 prefLabel "Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants" @default.
- Q66071395 prefLabel "Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants" @default.
- Q66071395 P1132 Q66071395-D7D194CF-FE96-4EC4-993C-ACF8520FD8AF @default.
- Q66071395 P1476 Q66071395-44A5F9AD-6D44-44A4-8FFA-86E0FCDD5A66 @default.
- Q66071395 P17 Q66071395-52FAD018-2160-4126-BA7A-590165103C3B @default.
- Q66071395 P17 Q66071395-57C67651-A68C-42F5-AB11-8F69124AE8C3 @default.
- Q66071395 P17 Q66071395-B7A9092E-11A3-490E-8C72-52DC556D278C @default.
- Q66071395 P17 Q66071395-E188C903-5C54-436D-B5C3-6225042A9617 @default.
- Q66071395 P1813 Q66071395-F3ED7C39-9A76-4579-815A-D92EB6D2E433 @default.
- Q66071395 P2899 Q66071395-6104EFB3-29E5-4AA7-8619-64A42CC93AC1 @default.
- Q66071395 P3098 Q66071395-982886A4-3334-4F44-A697-DF49411AA8F0 @default.
- Q66071395 P31 Q66071395-68671477-A75E-4D53-A6C9-33FD1A9C2A34 @default.
- Q66071395 P4135 Q66071395-73970B70-041F-4AFC-9B27-39C9AAEB3EFC @default.
- Q66071395 P580 Q66071395-0EE1AB66-00B9-40DC-8899-372D2C202CF8 @default.
- Q66071395 P582 Q66071395-D9E7B24B-633A-402C-8420-5D9CE1E7E4EF @default.
- Q66071395 P6099 Q66071395-1087B7A4-CC7E-4F75-8D76-635AE59C04E3 @default.
- Q66071395 P6099 Q66071395-33D3B05D-71C3-4E31-9CF8-FC22FD4ADBAD @default.
- Q66071395 P767 Q66071395-D83EE846-390B-4EDD-8414-73E53AD452D1 @default.
- Q66071395 P8363 Q66071395-0D3CADEC-382F-47D8-BE47-809AE3253274 @default.
- Q66071395 P1132 "+160" @default.
- Q66071395 P1476 "A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants" @default.
- Q66071395 P17 Q30 @default.
- Q66071395 P17 Q924 @default.
- Q66071395 P17 Q953 @default.
- Q66071395 P17 Q954 @default.
- Q66071395 P1813 "HVTN 120" @default.
- Q66071395 P2899 "+18" @default.
- Q66071395 P3098 "NCT03122223" @default.
- Q66071395 P31 Q30612 @default.
- Q66071395 P4135 "+40" @default.
- Q66071395 P580 "2018-01-16T00:00:00Z" @default.
- Q66071395 P582 "2019-09-30T00:00:00Z" @default.
- Q66071395 P6099 Q42824440 @default.
- Q66071395 P6099 Q5452194 @default.
- Q66071395 P767 Q212322 @default.
- Q66071395 P8363 Q78089383 @default.